Ikarian Capital Reports 6.7% Stake in Tenax Therapeutics, Inc. via Amended 13G

Ikarian Capital, LLC, along with Neil Shahrestani, filed a Schedule 13G/A on April 7, 2026, regarding their holdings in Tenax Therapeutics, Inc. (TENX). The reporting persons disclosed a combined beneficial ownership of 1,145,100 shares of common stock, representing 6.7% of the company's outstanding shares. This position includes 127,500 shares that may be acquired within 60 days through the exercise of options. The shares are held across the Ikarian Healthcare Master Fund, L.P. and various separately managed accounts. Ikarian Capital serves as the investment manager or sub-adviser to these entities, while Mr. Shahrestani maintains indirect control over the firm. The filing is an amendment to a previous disclosure, indicating an increase from the previously reported 0.0% ownership to the current 6.7% stake as of the event date on March 31, 2026. The reporting persons have certified that these securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.